GT201
DrugAutologous tumor infiltrating lymphocyte injection
NCT Number: NCT06144671
Expected to complete 7 to 18 evaluable subjects (patients with advanced solid tumors),3 dose groups.A modified "3+3" dose-escalation design is utilized,This includes both accelerated dose escalation and traditional "3+3" dose escalation.The first dose group is accelerated titration,The first dose group is an accelerated titration of 1 to 6 evaluable subjects;The second and third dose groups are based on the traditional "3+3" dose-escalation principle,The second and third dose groups are based on the traditional "3+3" dose-escalation principle, with 3 to 6 evaluable subjects enrolled respectively.
Interested in participating?
Request Info18 year–70 year
All sexes
Interventional
Phase 1 / Phase 2
The fifth medical center of the General Hospital of the Chinese people's Liberation Army, Beijing, Beijing Municipality, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Autologous tumor infiltrating lymphocyte injection
Time frame: 3 years
Safety Profile Measured By Grade ≥ 3 TREAs for CTCAE 5.0
Time frame: 3 years
Tumor imaging determines the changes in tumor size at baseline and after treatment.Tumor imaging evaluation according to RECIST v1.1
Contact information is provided by the study sponsor or research team.
Grit Biotechnology
Industry
A Single-Arm Phase I/II Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT201) for The Treatment Of Advanced Solid Tumors
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04928508
Solid Tumor, Adult
Oklahoma City, Oklahoma, United States
View Trial DetailsNCT06218914
Bronchial Neoplasms, Carcinoma, Bronchogenic
Duarte, California, United States
View Trial DetailsNCT06265688
Solid Tumor, Adult
Denver, Colorado, United States
View Trial DetailsNCT06824363
Adenocarcinoma Of Esophagus, Esophageal Adenocarcinoma
Orange, California, United States
View Trial Details